Radiotherapy of glioblastoma 15 years after the landmark Stupp’s trial: more controversies than standards?

The current standard of care of glioblastoma, the most common primary brain tumor in adults, has remained unchanged for over a decade. Nevertheless, some improvements in patient outcomes have occurred as a consequence of modern surgery, improved radiotherapy and up-to-date management of toxicity. Pa...

Full description

Saved in:
Bibliographic Details
Published inRadiology and oncology Vol. 52; no. 2; pp. 121 - 128
Main Authors Kazda, Tomas, Dziacky, Adam, Burkon, Petr, Pospisil, Petr, Slavik, Marek, Rehak, Zdenek, Jancalek, Radim, Slampa, Pavel, Slaby, Ondrej, Lakomy, Radek
Format Journal Article
LanguageEnglish
Published Poland Sciendo 01.06.2018
De Gruyter Poland
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The current standard of care of glioblastoma, the most common primary brain tumor in adults, has remained unchanged for over a decade. Nevertheless, some improvements in patient outcomes have occurred as a consequence of modern surgery, improved radiotherapy and up-to-date management of toxicity. Patients from control arms (receiving standard concurrent chemoradiotherapy and adjuvant chemotherapy with temozolomide) of recent clinical trials achieve better outcomes compared to the median survival of 14.6 months reported in Stupp's landmark clinical trial in 2005. The approach to radiotherapy that emerged from Stupp's trial, which continues to be a basis for the current standard of care, is no longer applicable and there is a need to develop updated guidelines for radiotherapy within the daily clinical practice that address or at least acknowledge existing controversies in the planning of radiotherapy.The goal of this review is to provoke critical thinking about potentially controversial aspects in the radiotherapy of glioblastoma, including among others the issue of target definitions, simultaneously integrated boost technique, and hippocampal sparing. In conjunction with new treatment approaches such as tumor-treating fields (TTF) and immunotherapy, the role of adjuvant radiotherapy will be further defined. The personalized approach in daily radiotherapy practice is enabled with modern radiotherapy systems.
ISSN:1318-2099
1581-3207
1581-3207
0485-893X
DOI:10.2478/raon-2018-0023